ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 354 • 2013 ACR/ARHP Annual Meeting

    Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union

    Siva Narayanan1, Yao Lu2, Richard Hutchings2 and Amanda Baskett2, 1Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, 2Ipsos Healthcare, London, United Kingdom

    Background/Purpose: Data on second line biologic patients who have experienced 1st line tumor necrosis factor inhibitor (TNF) failure and associated disease burden among patients (pts)…
  • Abstract Number: 1553 • 2013 ACR/ARHP Annual Meeting

    Responsiveness Of Health Related Quality Of Life Questionnaires To Treatment With Anti-TNF Therapy In Psoriatic Arthritis

    Zahi Touma1, Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Patient-reported outcomes (PRO) on Health Related Quality of Life (HRQoL) are increasingly used to assess responsiveness after treatment.  This study aimed to determine the…
  • Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol

    Arthur Kavanaugh1, Dafna D. Gladman2, Désirée M. van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
  • Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting

    Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register

    Saedis Saevarsdottir1, Michele Santacatterina2, Leszek Stawiarz3, Carl Turesson4, Helena Forsblad5, Lennart T.H. Jacobsson6 and Staffan Lindblad7, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 4Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 5Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 6Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 7Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
  • Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting

    Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up

    Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…
  • Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting

    Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice

    Gabriela Ávila1, Sara Marsal1, Arnald Alonso1, Carolina Diaz2, Estefanía Quesada-Masachs2, María López-Lasanta1 and Isabel Acosta3, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, 3Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
  • Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting

    The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis

    Lihi Eder1, Arane Thavaneswaran1, Vinod Chandran2, Richard J. Cook3 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…
  • Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting

    Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort

    Andra Negoescu1, Elena Nikiphorou2, Anshuman P. Malaviya3, Andrew Badcock3, John D. Fitzpatrick3,4, Calum T. Goudie3,4 and Andrew J. Ostor3, 1Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, 2Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, 3Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, 4University of Cambridge Medical School, Cambridge, United Kingdom

    Background/Purpose:   Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
  • Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting

    Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis

    Odirlei Andre Monticielo1, Karen Regina Rosso Schons2, Cristiane Faccin Knob2, Walter Neumaier2, Maristela de Oliveira Beck2 and André Avelino Costa Beber2, 1Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Universidade Federal de Santa Maria, Santa Maria, Brazil

    Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…
  • Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting

    Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry

    ŽIga Rotar1 and Matija Tomsic2, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia

    Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
  • Abstract Number: 310 • 2013 ACR/ARHP Annual Meeting

    Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials

    Philip J. Mease1, Arthur Kavanaugh2, Dafna D. Gladman3, Adewale O. Adebajo4, Juan J. Gomez-Reino5, Jürgen Wollenhaupt6, Maurizio Cutolo7, Georg Schett8, Eric Lespessailles9, Kamal Shah10, ChiaChi Hu10, Randall M. Stevens10, Christopher J. Edwards11 and Charles A. Birbara12, 1Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 2University of California San Diego, San Diego, CA, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, 5Rheumatology, Hospital Clinico Universitario, Santiago, Spain, 6Schön Klinik Hamburg Eilbek, Hamburg, Germany, 7University of Genova, Genova, Italy, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 9University of Orléans, Orléans, France, 10Celgene Corporation, Warren, NJ, 11University of Southampton, Southampton, United Kingdom, 12University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy and safety of…
  • Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting

    Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen

    Jaime Pachon1, Alan Kivitz2, Kay-Uwe Heuer3 and Uwe Pichlmeier3, 1Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, 2Altoona Center for Clinical Research, Duncansville, PA, 3medac GmbH, Wedel, Germany

    Background/Purpose:  Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
  • Abstract Number: 311 • 2013 ACR/ARHP Annual Meeting

    Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)

    Christopher J. Edwards1, Francisco J. Blanco2, Jeffrey Crowley3, ChiaChi Hu4, Randall M. Stevens4 and Charles A. Birbara5, 1University of Southampton, Southampton, United Kingdom, 2INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, 3Bakersfield Dermatology, Bakersfield, CA, 4Celgene Corporation, Warren, NJ, 5University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 3 compared the efficacy/safety of APR with placebo (PBO) in…
  • Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting

    COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic

    Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
  • Abstract Number: 317 • 2013 ACR/ARHP Annual Meeting

    Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials

    Maurizio Cutolo1, Philip J. Mease2, Dafna D. Gladman3, Arthur Kavanaugh4, Adewale O. Adebajo5, Juan J. Gomez-Reino6, Jürgen Wollenhaupt7, Georg Schett8, Eric Lespessailles9, Kamal Shah10, ChiaChi Hu10, Randall M. Stevens10, Christopher J. Edwards11 and Charles A. Birbara12, 1University of Genova, Genova, Italy, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University of California San Diego, San Diego, CA, 5Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, 6Hospital Clinico Universitario, Santiago, Spain, 7Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 9University of Orléans, Orléans, France, 10Celgene Corporation, Warren, NJ, 11University of Southampton, Southampton, United Kingdom, 12University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
  • « Previous Page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology